| Heart Failure (HF) |
1 |
1 |
| Heart |
0 |
0.91 |
| Type 2 Diabetes Mellitus |
0 |
0.86 |
| Coronary Artery Disease (CAD) |
0 |
0.73 |
| Hypertension |
0 |
0.58 |
| Cardiovascular Risk Management |
0 |
0.54 |
| Cardiovascular Imaging |
0 |
0.51 |
| Biomarker |
0 |
0.26 |
| SGLT2 Inhibitor |
0 |
0.26 |
| B-Type Natriuretic Peptide |
0 |
0.1 |
| Receptors |
0 |
0.1 |
| Angiotensin II Receptor Blockade |
0 |
0.09 |
| Myocardial Infarction (MI) |
0 |
0.09 |
| Troponin |
0 |
0.07 |
| Weight Loss |
0 |
0.07 |
| Pulmonary Embolism |
0 |
0.06 |
| Deep Venous Thrombosis |
0 |
0.05 |
| Renal Disease |
0 |
0.05 |
| Weight Management |
0 |
0.05 |
| ACE Inhibitor |
0 |
0.03 |
| Artery |
0 |
0.03 |
| Blood |
0 |
0.03 |
| Cardiovascular disease |
0 |
0.03 |
| Clinical Guidelines |
0 |
0.03 |
| Diuretics |
0 |
0.03 |
| DPP-4 Inhibitors |
0 |
0.03 |
| Ejection Fraction |
0 |
0.03 |
| Endocrinology |
0 |
0.03 |
| Exercise |
0 |
0.03 |
| Kidney |
0 |
0.03 |
| Metabolism |
0 |
0.03 |
| Michigan |
0 |
0.03 |
| Nutrition |
0 |
0.03 |
| Pollex |
0 |
0.03 |
| Social Determinants of Health |
0 |
0.03 |
| Sulfonylureas |
0 |
0.03 |